Clinical trials: Obese Subjects
Type 2 Diabetes, Diabetes Mellitus, Type 2
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation…
- Conditions
- Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases
- Trial name
- NCT01474161
- Testing
- GFT505 120mg - old formulation, GFT505 120mg - new formulation, GFT505 180mg - new formulation
- Where
- France
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Genfit
Type 2 Diabetes Mellitus
A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
A phase 2 study in two parts (A \& B) designed to evaluate the effect of MEDI0382 on Hepatic Glycogen Metabolism in subjects with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT03555994
- Testing
- MEDI0382, Liraglutide
- Where
- 3 sites in Netherlands, Sweden and 1 more
- Volunteers
- 51 people
- Sponsor
- MedImmune LLC
Solid Tumor, Obesity
Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects
This study aims to evaluate the safety, tolerability, pharmacokinetics, and food effect of a new investigational medicine called SCB0020160 in healthy adult men. This is the first time SCB0020160 will be administered to humans.
- Conditions
- Solid Tumor, Obesity, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT07682337
- Testing
- SCB0020160
- Where
- Australia
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- SCBIO Inc.
Overweight or Obesity
A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes
This study aims to evaluate the efficacy and dose-response relationship of HRS9531 injection compared with placebo in reducing body weight in obese subjects without diabetes after 24 weeks of treatment.
- Trial name
- NCT05881837
- Testing
- HRS9531 injection
- Where
- 25 sites in China
- Volunteers
- 249 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Overweight and Obesity
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity
- Trial name
- EMBRAZE (NCT06445075)
- Testing
- Apitegromab, Tirzepatide
- Where
- 7 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Scholar Rock, Inc.
Acute Kidney Injury
PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects
The main purpose of this trial is to demonstrate the safety, tolerability and pharmacokinetics (PK) of CXA-10 and its metabolite(s) administered as multiple ascending oral doses over 14 days to healthy obese male volunteers.
- Trial name
- NCT02460146
- Testing
- CXA-10
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Complexa, Inc.
PreDiabetes, Pre Diabetes
STAR Study Investigating Performance and Safety of the Medical Device SiPore15™
The primary objective of STAR01 is to evaluate the performance and safety of the medical device (class IIb) SiPore15™ after a 12-week long treatment in the target population of obese and overweight subjects with prediabetes or…
- Conditions
- PreDiabetes, Pre Diabetes, Prediabetic State, Type2 Diabetes
- Trial name
- NCT03823027
- Testing
- SiPore15™
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 43 people
- Sponsor
- Sigrid Therapeutics AB
Diabetes Mellitus Type 2
Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects
This study is designed to assess the safety, tolerability and pharmacokinetics of multiple oral 200-mg doses of PF-05175157 administered twice daily for 14 days in healthy overweight and obese subjects.
- Trial name
- NCT01807377
- Testing
- PF-05175157, Midazolam
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
The ValenTx Endo Bypass System in Obese Subjects
The purpose of this study is to collect clinical data to support the use of the ValenTx Endo Bypass System to improve weight loss and the resolution of comorbidities in obese subjects.
- Trial name
- NCT02954003
- Testing
- Endo Bypass System
- Where
- 3 sites in Canada, Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- ValenTx, Inc.
Central Abdominal Bulging
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat
This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.
- Trial name
- AbCONTOUR1 (NCT02397499)
- Testing
- LIPO-202
- Where
- 31 sites in United States
- Volunteers
- 800 people
- Sponsor
- Neothetics, Inc
Overweight, Obesity
STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity
This study will look at the change in participants' body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 6 (NCT03811574)
- Testing
- Semaglutide
- Where
- 28 sites in Japan, South Korea
- Volunteers
- 401 people
- Sponsor
- Novo Nordisk A/S
Weight Loss
Evaluation of GCB-70 in Overweight Subjects
Clinical evaluation of GCB-70 in overweight subjects: An Add-On Study
- Trial name
- NCT02703025
- Testing
- GCB-70
- Where
- India
- Volunteers
- 105 people
- Sponsor
- Chemical Resources
Obesity, Type 2 Diabetes
An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adult subjects with type 2 diabetes mellitus.
- Trial name
- NCT02324491
- Testing
- ZGN-440 for Injectable Suspension
- Where
- 16 sites in Australia
- Volunteers
- 152 people
- Sponsor
- Zafgen, Inc.
Obesity
The Safety and Efficacy of the ReShape Intragastric Balloon in Obese Subjects
The study evaluated the safety and efficacy of the ReShape Intragastric Balloon as an adjunct to diet and exercise in obese patients compared with diet and exercise alone.
- Trial name
- NCT01061385
- Testing
- ReShape Intragastric Balloon, Control Arm
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ReShape Lifesciences
Healthy Subjects
A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects
This trial adopts a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HEC-007 Injection after single-dose…
- Trial name
- NCT07102251
- Testing
- HEC-007 injection
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Bstructive Sleep Apnea (OSA) and Obesity
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects with Obstructive Sleep Apnea (OSA) and Obesity
- Trial name
- NCT06974851
- Testing
- HRS9531
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Hypercholesterolemia, Cardiovascular Risk Factor
Effect of Totum-070 on Lipid Metabolism in Moderate Hypercholesterolemic Subjects
This clinical study aims to assess the efficacy of TOTUM-070, a mix of 5 plant extracts, on lipid metabolism in moderate hypercholesterolemic subjects.
- Conditions
- Hypercholesterolemia, Cardiovascular Risk Factor, Dyslipidemias, Overweight and Obesity
- Trial name
- HEART (NCT04760951)
- Testing
- TOTUM-070
- Where
- 4 sites in France, Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Central Abdominal Bulging
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)
This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.
- Trial name
- NCT02398188
- Testing
- LIPO-202
- Where
- 35 sites in United States
- Volunteers
- 793 people, healthy volunteers welcome
- Sponsor
- Evofem Inc.
Obesity
A First-Time-In-Human Study in Healthy Subjects
This is a first-time-in-human study. The overall purpose of the study is to assess whether the drug is safe and well tolerated after single, increasing doses.
- Trial name
- FTIH (NCT00857883)
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight.
- Trial name
- STEP HFpEF DM (NCT04916470)
- Testing
- Semaglutide
- Where
- 180 sites in United States, Argentina and 14 more
- Volunteers
- 617 people
- Sponsor
- Novo Nordisk A/S